Optimization of first‐line systemic therapy in patients with advanced clear cell renal cell carcinoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimization of first‐line systemic therapy in patients with advanced clear cell renal cell carcinoma
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF UROLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-12-08
DOI
10.1111/iju.15103
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis
- (2022) Pasquale Lombardi et al. CANCER TREATMENT REVIEWS
- European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
- (2022) Börje Ljungberg et al. EUROPEAN UROLOGY
- Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
- (2022) Nizar M Tannir et al. Journal for ImmunoTherapy of Cancer
- Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
- (2022) Robert J Motzer et al. Journal for ImmunoTherapy of Cancer
- Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
- (2022) W. Kimryn Rathmell et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
- (2022) Robert J Motzer et al. LANCET ONCOLOGY
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
- (2021) Satoshi Tamada et al. International Journal of Clinical Oncology
- Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
- (2021) Eric Jonasch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
- (2021) Robert J. Motzer et al. JAMA Oncology
- Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
- (2020) T.K. Choueiri et al. ANNALS OF ONCOLOGY
- Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
- (2020) Nizar M. Tannir et al. CLINICAL CANCER RESEARCH
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
- (2020) Robert J. Motzer et al. NATURE MEDICINE
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214
- (2019) Bernard Escudier et al. EUROPEAN UROLOGY
- Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
- (2019) Motohide Uemura et al. CANCER SCIENCE
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
- (2013) M. J. Brauer et al. CLINICAL CANCER RESEARCH
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients
- (2009) Sei Naito et al. EUROPEAN UROLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now